Skip to main content
. Author manuscript; available in PMC: 2011 Feb 15.
Published in final edited form as: Cancer. 2010 Feb 15;116(4 Suppl):1126–1133. doi: 10.1002/cncr.24801

Figure 2.

Figure 2

Median progression-free survival of patients with advanced grade 1 or 2 follicular lymphoma treated with Zevalin/yttrium-90 ibritumomab tiuxetan consolidation after first remission (thin line) compared to controls (thick line) [reproduced with permission from Morschhauser et al., J Clin Oncol 2008; 26:5160.]19